Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by A. Fu
OUTCOMES OF APPROPRIATE VERSUS INAPPROPRIATE DE-ESCALATION OF P2Y12 INHIBITOR THERAPY POST PERCUTANEOUS CORONARY INTERVENTION: A RETROSPECTIVE COHORT STUDY.
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Current guidelines recommend ticagrelor or prasugrel as first-line agents for patients with acute coronary syndromes (ACS). While de-escalation from ticagrelor or prasugrel to clopidogrel is common practice, this may be considered “inappropriate” when a change between potent agents is an option. This practice may put patients at risk of ischemic complications.
INCIDENCE AND RATIONALE FOR P2Y12 INHIBITOR SWITCHING IN PATIENTS WITHIN 1 YEAR OF PERCUTANEOUS CORONARY INTERVENTION
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. FiguresDual antiplatelet therapy (DAPT), with aspirin and a P2Y12 inhibitor, is the standard therapy for patients with acute coronary syndrome (ACS) or after percutaneous coronary intervention (PCI). Clopidogrel has traditionally been the P2Y12 agent of choice.
APPROPRIATE VERSES INAPPROPRIATE DE-ESCALATION OF P2Y12 INHIBITOR THERAPY POST PERCUTANEOUS CORONARY INTERVENTION: A RETROSPECTIVE COHORT STUDY
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. FiguresCurrent guidelines recommend ticagrelor or prasugrel as first line agents in the context of patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). De-escalation from ticagrelor or prasugrel to clopidogrel, is a common occurrence in clinical practice.
DO THE DAPT AND PRECISE-DAPT SCORES PROVIDE CONCORDANT RECOMMENDATIONS FOR DURATION OF P2Y12 INHIBITOR TREATMENT AFTER PERCUTANEOUS CORONARY INTERVENTION?
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. FiguresDual antiplatelet therapy (DAPT), with aspirin and a P2Y12 inhibitor, is the standard therapy for patients following percutaneous coronary intervention (PCI). Length of treatment with DAPT has been controversial despite large studies. Current guidelines recommend treatment duration to be individualized based on risk of ischemia and bleeding.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with A.
Contact A., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack